Maryam Lustberg, Director Breast Center/Chief Breast Oncology at Yale University School of Medicine, shared a post by Lisa Larkin, Founder and Co-Director at OncoMenopause Consortium, on LinkedIn, adding:
“A few thoughts from our session at San Antonio Breast Cancer Symposium 2025:
There is tremendous interest in learning more about menopause care among the breast oncology community members. The room was packed and engagement with in person and online questions quite high.
There are varying levels of comfort on tackling the nuances of vaginal hormone therapy and systemic therapy. This is ok. We can talk and debate these and highlight gray zones to our patients
It is more clear than ever to me that we need multi D collaborative research and we need innovative funding strategies to make evidenced based oncomenopause care a reality.”
Quoting Lisa Larkin‘s post:
“I’m looking forward to speaking with my colleagues Dr. Lustberg and Dr. Kling at the 2025 San Antonio Breast Cancer Symposium about menopause management in breast cancer survivors!
We will be discussing if and when menopausal hormone therapy (MHT) can ever be considered an option, exploring the latest evidence, guidelines, and clinical considerations for survivors.
I hope you can join us for this important session!”
More posts featuring Maryam Lustberg, Lisa Larkin on OncoDaily.
You Can Also Read:
15 Posts Not to Miss from SABCS 2025, Part 1
20 Posts Not to Miss from SABCS 2025, Part 2
